Disappearance of Angina Pectoris by Lipid-Lowering in Type III Hyperlipoproteinemia

被引:8
作者
Cho, Eun Jeung [1 ]
Min, Yun Joo [1 ]
Oh, Min Seok [1 ]
Kwon, Jee Eun [1 ]
Kim, Jeung Eun [1 ]
Kim, Chee Jeong [1 ]
机构
[1] Chung Ang Univ, Coll Med, Dept Internal Med, Div Cardiol, Seoul 156756, South Korea
关键词
LONG-TERM EFFICACY; GEMFIBROZIL; FENOFIBRATE; COMBINATION; SAFETY;
D O I
10.1016/j.amjcard.2010.10.063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type III hyperlipoproteinemia is a rare familial disease characterized by marked elevations of serum cholesterol and triglyceride levels caused by an accumulation of remnant lipoproteins in apolipoprotein E2/E2 homozygotes. It is associated with an increased risk for premature atherosclerotic vascular disease. A 55-year-old woman was diagnosed as having type :EH hyperlipoproteinemia on the basis of skin lesions, serum lipid levels, lipid electrophoresis, and apolipoprotein E genotyping and stable angina pectoris on the basis of typical symptoms and treadmill exercise electrocardiographic results. After 1 year of combination therapy with atorvastatin and fenofibrate, skin xanthomata disappeared, leaving minimal remnants. In addition, there was no exertional chest pain, and treadmill exercise electrocardiographic results were negative. This finding was confirmed by coronary computed tomographic angiography. This case suggests that proper medical therapy can induce the regression of uncomplicated coronary lesions in type III hyperlipoproteinemia. (c) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:793-796)
引用
收藏
页码:793 / 796
页数:4
相关论文
共 10 条
[1]   TYPE-III HYPERLIPOPROTEINEMIA - DIAGNOSIS, MOLECULAR DEFECTS, PATHOLOGY, AND TREATMENT [J].
BREWER, HB ;
ZECH, LA ;
GREGG, RE ;
SCHWARTZ, D ;
SCHAEFER, EJ .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) :623-640
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]   Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia [J].
Ellen, RLB ;
McPherson, R .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (4A) :60B-65B
[4]  
FEUSSNER G, 1992, CLIN INVESTIGATOR, V70, P1027
[5]   Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease [J].
Hopkins, PN ;
Wu, LL ;
Hunt, SC ;
Brinton, EA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (07) :1003-1012
[6]   THE HYPOLIPIDEMIC EFFECTS OF LOVASTATIN AND CLOFIBRATE ALONE AND IN COMBINATION IN PATIENTS WITH TYPE-III HYPERLIPOPROTEINEMIA [J].
ILLINGWORTH, DR ;
OMALLEY, JP .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (04) :403-409
[7]   Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis - A 28-year clinical course [J].
Kawashiri, MA ;
Higashikata, T ;
Takata, M ;
Katsuda, S ;
Miwa, K ;
Nohara, A ;
Inazu, A ;
Kobayashi, J ;
Shimizu, M ;
Koizumi, J ;
Mabuchi, H .
CIRCULATION JOURNAL, 2005, 69 (06) :746-751
[8]   TREATMENT OF TYPE-III HYPERLIPOPROTEINEMIA WITH GEMFIBROZIL TO RETARD PROGRESSION OF CORONARY-ARTERY DISEASE [J].
KUO, PT ;
WILSON, AC ;
KOSTIS, JB ;
MOREYRA, AB ;
DODGE, HT .
AMERICAN HEART JOURNAL, 1988, 116 (01) :85-90
[9]   LIPOPROTEIN COMPOSITION CHANGES INDUCED BY FENOFIBRATE IN DYSBETALIPOPROTEINEMIA TYPE-III [J].
LUSSIERCACAN, S ;
BARD, JM ;
BOULET, L ;
NESTRUCK, AC ;
GROTHE, AM ;
FRUCHART, JC ;
DAVIGNON, J .
ATHEROSCLEROSIS, 1989, 78 (2-3) :167-182
[10]   Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia [J].
van Dam, M ;
Zwart, M ;
de Beer, F ;
Smelt, AHM ;
Prins, MH ;
Trip, MD ;
Havekes, LM ;
Lansberg, PJ ;
Kastelein, JJP .
HEART, 2002, 88 (03) :234-238